Patents Examined by Traviss C. McIntosh, III
  • Use of secoisolariciresinol diglucosides (SDGS) and related compounds for protection against radiation and chemical damage
    Patent number: 10966995
    Abstract: The invention provides compositions and methods for radioprotection and chemoprevention using therapeutic and prophylactics methods of using (S,S)-SDG (R,R)-SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, analogs thereof, stereoisomers thereof and other related molecules.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 6, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Melpo Christofidou-Solomidou
  • Compounds and compositions for treating conditions associated with sting activity
    Patent number: 10961270
    Abstract: This disclosure features chemical entities (e.g., a compound that modulates (e.g., agonizes) Stimulator of Interferon Genes (STING), or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that are useful, e.g., for treating a condition, disease or disorder in which a decrease or increase in STING activity (e.g., a decrease, e.g., a condition, disease or disorder associated with repressed or impaired STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: March 30, 2021
    Assignee: Innate Tumor Immunity, Inc.
    Inventors: Gary Glick, Shomir Ghosh, Edward James Olhava, William R. Roush, Roger Jones
  • 4?-fluoro-2?-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 10953030
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: March 23, 2021
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
    Patent number: 10953029
    Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula (I) and derivatives thereof.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: March 23, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Vinay M. Girijavallabhan
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10953032
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 23, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dharmpal S. Dodd, Brian E. Fink, Yong Zhang
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10947263
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 16, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lan-Ying Qin, Zheming Ruan, Libing Chen, Scott Hunter Watterson, Brian E. Fink
  • Steroid saponins with anti-cancer activity
    Patent number: 10925887
    Abstract: The present invention relates to a new class of steroid saponins that have interesting biological activity. In particular the present invention relates to a class of steroid saponins in which the sugar moiety has been selectively functionalised to introduce a moiety that contains either, (i) a hydrogen ion donor, (ii) a hydrogen ion acceptor or (iii) a combination thereof. These new, water-soluble compounds are found to not only have potent anti-cancer properties per se but also have the ability to promote the immune response in a subject and can thus act as adjuvants for T-cell activation in cancer therapy.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: February 23, 2021
    Inventors: Peter Kelly, Philip Andrew Marshall
  • Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition
    Patent number: 10919926
    Abstract: Problems of the present invention is to provide a novel compound or a salt thereof capable of activating natural killer T cell, a natural killer T cell activating agent containing such a compound or a salt thereof, and a pharmaceutical composition. The compound of the present invention is a compound represented by the following formula (1) or a salt thereof. It is preferable that total carbon number of the number of carbon atoms in the monovalent hydrocarbon group in R1 in the formula (1) excluding a sustitutent and the number of carbon atoms in the divalent hydrocarbon group in X1 is 5 to 50. The natural killer T cell activating agent contains the aforementioned compound or a salt thereof. The pharmaceutical composition contains the aforementioned compound or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 16, 2021
    Assignees: KEIO UNIVERSITY, REGiMMUNE CORPORATION
    Inventors: Shinsuke Inuki, Natsumi Hirata, Emi Kashiwabara, Junichiro Kishi, Toshihiko Aiba, Yukari Fujimoto
  • Liver specific delivery-based gemcitabine prodrug nucleoside cyclic phosphate compound, and application thereof
    Patent number: 10913765
    Abstract: Provided are a liver specific delivery (LSD)-based anticancer prodrug nucleoside cyclic phosphate compound and an application thereof, and in particular, a compound represented by formula (I) as well as isomers, pharmaceutically acceptable salts, hydrates, and solvates thereof, and corresponding pharmaceutical compositions. Also provided is an application of the compound alone or in combination with other anticancer drugs in anticancer area, particularly the treatment of hepatocellular carcinoma (HHC).
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: February 9, 2021
    Inventors: Zhijian Xi, Huaqiang Xu, Chunping Lu, Zhongshan Wu
  • Liver specific delivery-based entecavir prodrug, nucleoside cyclic phosphate compound, and application thereof
    Patent number: 10913766
    Abstract: Disclosed is a liver specific delivery (LSD)-based entecavir antiviral prodrug, i.e., a nucleoside cyclic phosphate compound, and the application thereof. Specifically, disclosed are a compound as represented by formula (I) and isomers, pharmaceutically acceptable salts, hydrates, and solvates of the compound, and a corresponding pharmaceutical composition. Also disclosed is the application of the compound of the present invention, used separately or used in combination with other antiviral drugs, against viruses, especially the application against hepatitis B virus (HBV).
    Type: Grant
    Filed: June 20, 2020
    Date of Patent: February 9, 2021
    Inventors: Zhijian Xi, Huaqiang Xu, Chunping Lu, Zhongshan Wu
  • Triterpene saponin analogues
    Patent number: 10906926
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 2, 2021
    Assignees: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER
    Inventors: David Y. Gin, Eric Chea, Alberto Fernandez-Tejada, Jeffrey Gardner, Jason Lewis, Philip Livingston, J. Tyler Martin, Lars Nordstroem, Naga Vara Kishore Pillarsetty, Govind Ragupathi, Derek Tan
  • Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
    Patent number: 10906928
    Abstract: A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: February 2, 2021
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Adel Moussa, Jean-Pierre Sommadossi
  • Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
    Patent number: 10899788
    Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 26, 2021
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Stephane Bogen, David Dukhan, Guillaume Brandt, Claire Pierra Rouviere, Cyril B. Dousson, Francois-Rene Alexandre
  • Use of UAP inhibitors to inhibit flux through the hexosamine biosynthetic pathway
    Patent number: 10899784
    Abstract: Disclosed are UAP inhibitors to inhibit glucose flux in the hexosamine biosynthetic pathway and methods of treating a disease using the inhibitors.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: January 26, 2021
    Assignee: The Johns Hopkins University
    Inventors: Kevin J. Yarema, Christopher T. Saeui, Alfredo Quinones-Hinojosa, Sagar Ramesh Shah
  • Cytarabine prodrug nucleoside cyclic phosphate compound based on liverspecific delivery and use
    Patent number: 10899787
    Abstract: Disclosed are an anticancer prodrug nucleoside cyclic phosphate compound based on liver-specific delivery (LSD) technology and the use thereof, in particular, provided are a compound of formula (I) and an isomer, a pharmaceutically acceptable salt, a hydrate, a solvate and a corresponding pharmaceutical composition thereof, and the use of the compound alone or in combination with other anticancer drugs against cancer, especially in treating hepatic carcinoma (HCC).
    Type: Grant
    Filed: June 20, 2020
    Date of Patent: January 26, 2021
    Inventors: Zhijian Xi, Huaqiang Xu, Chunping Lu, Zhongshan Wu
  • Aminoglycoside derivatives and uses thereof in treating genetic disorders
    Patent number: 10899785
    Abstract: Novel aminoglycosides, represented by Formulae Ia and Ib, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: January 26, 2021
    Assignee: ELOXX PHARMACEUTICALS LTD.
    Inventors: Timor Baasov, Shmuel Tuvia
  • Carboxylated 2?-amino-LNA nucleotides and oligonucleotides comprising the same
    Patent number: 10894962
    Abstract: The invention proves an oligonucleotide comprising one or more carboxylated 2?-amino-LNA nucleotide units. The invention also provides a method of transfecting cells with the oligonucleotide, a method of treating a human or animal by therapy using the oligonucleotide, and a pharmaceutical composition comprising the oligonucleotide.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: January 19, 2021
    Assignee: BIONTECH DELIVERY TECHNOLOGIES GMBH
    Inventor: Steffen Panzner
  • Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
    Patent number: 10894804
    Abstract: A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: January 19, 2021
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Adel Moussa, Jean-Pierre Sommadossi
  • Composition of HMB and ATP and methods of use
    Patent number: 10888576
    Abstract: The present invention provides a composition comprising HMB and ATP. Methods of administering HMB and ATP to an animal are also described. HMB and ATP are administered to increase power and strength. The combination of HMB and ATP together has a synergistic effect, which results in a surprising and unexpected level of improvement in power and strength. HMB and ATP are also administered to increase lean body mass and muscle hypertrophy and to prevent typical declines in performance that are characteristic of overreaching.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: January 12, 2021
    Assignee: Metabolic Technologies, Inc.
    Inventors: Shawn Baier, Larry Kolb, John Rathmacher
  • Method of treating leukemia
    Patent number: 10881680
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: January 5, 2021
    Assignee: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle